Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service dialysis access cases in Rhode Island: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (245 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 1,101 | 51% |
| 2020 | 4 | 991 | 53% |
| 2021 | 4 | 900 | 57% |
| 2022 | 4 | 789 | 60% |
| 2023 | 5 | 708 | 64% |
| 2024 | 3 | 655 | 66% |
| 2025 from claims | – | 562 454–660 | 67% |
| 2026 forecast | – | 584 457–733 | 66% |
| 2027 forecast | – | 590 437–779 | 66% |
| 2028 forecast | – | 595 421–822 | 67% |
| 2029 forecast | – | 601 408–862 | 67% |
| 2030 forecast | – | 607 397–900 | 67% |
AV fistula and graft creation, access circuit angioplasty and stenting. Professional codes (what the surgeon bills): CPT 36821, 36830, 36902, 36903, 36905, 36906, 36818, 36819.
Since 2021 dialysis (ESRD) patients may join Medicare Advantage, and they have moved to it far faster than the county average, so fee-for-service decline here overstates the real one even after adjustment.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Rhode Island; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% surgery center. The share outside the hospital has moved +5 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Surgery center |
|---|---|
| 2026 · ~580 | ~580 |
| 2027 · ~590 | ~590 |
| 2028 · ~600 | ~600 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 109 | 13,452−13%/yr | −13%/yr | 7.7 | 80% | 12,500 in 2030−1.2%/yr |
| New Jersey | 58 | 7,071−13%/yr | −13%/yr | 7.0 | 70% | 7,590 in 2030+1.2%/yr |
| Pennsylvania | 59 | 4,916−14%/yr | −14%/yr | 3.8 | 50% | 4,300 in 2030−2.2%/yr |
| Massachusetts | 31 | 2,905−7.2%/yr | −7.2%/yr | 3.2 | 22% | 3,070 in 2030+0.9%/yr |
| Connecticut | 14 | 1,941−9.9%/yr | −9.9%/yr | 6.1 | 87% | 1,830 in 2030−1%/yr |
| New Hampshire | 6 | 354−13%/yr | −13%/yr | 1.6 | 0% | 380 in 2030+1.2%/yr |
| Maine | 4 | 340−15%/yr | −15%/yr | 2.2 | 5% | 390 in 2030+2.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 4 | 346−12%/yr | −12%/yr | 3.60.7× | 54% | 380 in 2030+1.5%/yr |
| Superficial venous ablation | 5 | 302−2.7%/yr | −2.7%/yr | 3.10.9× | 100% | 410 in 2030+5.3%/yr |
| Carotid revascularization | 3 | 142+2.9%/yr | +2.9%/yr | 1.51.5× | 0% | 70 in 2030−11%/yr |
Dialysis access in every state, and its device makers · Every procedure market in Rhode Island · Every state · Compare with New York
BD leads with 80% of company spending on these surgeons in 2025, +64 pts on 2024.
In 2025, 4 companies reported engagement with Rhode Island’s surgeons worth $437 in consulting, speaking, meals and travel tied to these products, about $146 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.